title: Does anticoagulant therapy improve pregnancy outcome equally, regardless of specific thrombophilia type?
abstract: The study was conducted to evaluate the effect of anticoagulant therapy in women with thrombophilia and to detect the possible differences among carriers of mutations (factor V [FV] Leiden and FIIG20210) and those with natural anticoagulant deficiency. The 4-year prospective investigation included 85 pregnant women, with a history of recurrent fetal loss (RFL). They were treated with prophylactic doses of low-molecular-weight heparin (nadroparin) starting from 6 to 8 weeks of gestation. Pregnancy outcomes were evaluated based on the thrombophilia type. Carriers of thrombophilic mutations had a live birth rate of 93%, compared to 41.6% for women with natural anticoagulant deficiencies. Significant differences between the groups were also observed for intrauterine fetal death, intrauterine growth restriction, and postpartum thrombosis. The optimal therapy for women with natural anticoagulant deficiency and RFL remains unclear and future prospective study with a large number of patients is required to determine the best treatment for these severe thrombophilic conditions.
authors.affiliation: 1Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
authors.forename: Mirjana
authors.initials: M
authors.lastname: Kovac
authors.forename: Zeljko
authors.initials: Z
authors.lastname: Mikovic
authors.forename: Gorana
authors.initials: G
authors.lastname: Mitic
authors.forename: Valentina
authors.initials: V
authors.lastname: Djordjevic
authors.forename: Vesna
authors.initials: V
authors.lastname: Mandic
authors.forename: Ljiljana
authors.initials: L
authors.lastname: Rakicevic
authors.forename: Dragica
authors.initials: D
authors.lastname: Radojkovic
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011446:Prospective Studies; D012307:Risk Factors; D019851:Thrombophilia / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants